Obinutuzumab-based immunochemotherapy and maintenance therapy resulted in longer progression-free survival than rituximab-based therapy. High-grade adverse events were more common with obinutuzumab-based chemotherapy. (Funded by F. Hoffmann-La Roche; GALLIUM ClinicalTrials.gov number, NCT01332968 .) …
See more from Akiva Diamond
In the Gallium trial looking at the role of Obinutuzumab vs rituximab in the first line treatment of FL, there was a 6% PFS benefit but no improvement in CR rates.